Amgen Inc.
Amgen Inc (AMGN) is a large-cap biotechnology company specialising in human therapeutics, particularly biologic medicines. With a market capitalisation around $162 billion, Amgen generates revenue from established products across oncology, nephrology, inflammation and cardiovascular care, while investing heavily in a diverse R&D pipeline of biologics and novel therapies. The company benefits from recurring revenue from long-tenured biologics, a history of steady free cash flow and a shareholder-friendly dividend policy, but faces typical sector risks: clinical trial setbacks, biosimilar competition, pricing pressure and regulatory scrutiny. Investors should watch product patent expiries, pipeline readouts and any M&A activity. This summary is for educational purposes only and not personalised investment advice; suitability depends on an investor’s goals, timeframe and risk tolerance, and returns are not guaranteed.
Why It's Moving
AMGN Stock Warning: Why Analysts See -11% Downside Risk
- Bernstein labels 2026 a 'waiting year' for MariTide, citing delays in obesity drug momentum and emerging risks to Repatha from Merck's competing pricing.
- FDA safety alert on Tavneos flags ~76 liver injury cases, raising prescribing caution and regulatory overhang that could dent sales.
- Analysts' mixed consensus points to modest downside from current levels near $345, driven by $5B denosumab biosimilar headwinds despite buy ratings from some.
AMGN Stock Warning: Why Analysts See -11% Downside Risk
- Bernstein labels 2026 a 'waiting year' for MariTide, citing delays in obesity drug momentum and emerging risks to Repatha from Merck's competing pricing.
- FDA safety alert on Tavneos flags ~76 liver injury cases, raising prescribing caution and regulatory overhang that could dent sales.
- Analysts' mixed consensus points to modest downside from current levels near $345, driven by $5B denosumab biosimilar headwinds despite buy ratings from some.
When is the next earnings date for Amgen Inc. (AMGN)?
Amgen's next earnings release is estimated for April 30, 2026, after market close, covering the first quarter of 2026 (Q1 2026). This date aligns with the company's historical pattern of late-April announcements for Q1 results, though it remains unconfirmed by the company. A conference call is typically scheduled for 4:30 PM ET following the release.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Amgen's stock as it has a potential for future gains.
Financial Health
Amgen is performing well with strong revenue, profits, and cash flow, indicating solid financial health.
Dividend
Amgen's average dividend yield of 2.72% makes it a decent option for investors seeking dividends. If you invested $1000 you would be paid $27.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases.
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
Baskets Featuring AMGN
Hypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketProfit Sharers
These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.
Published: June 17, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Established Biologics Revenue
Amgen’s marketed biologics provide recurring sales and predictable cash flow, though revenue can be affected by patent loss and biosimilar entrants.
Pipeline & R&D Focus
A deep R&D pipeline drives long-term potential; positive trial results can re-rate the business, while failures can materially affect value.
Global Market Exposure
Amgen sells worldwide, benefiting from geographic diversification, but faces regional pricing and regulatory differences that can influence performance.
Compare Amgen with other stocks
Amgen vs Gilead Sciences
Amgen vs Gilead Sciences: Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
